RxDoctor Payments Data

Amy Long, APRN

Family · Chattanooga, TNNPI 1164839494

Payments from drug & device makers

$4,006in general payments, 2019–2025

Across 191 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Sumitomo Pharma America, Inc.$794
  • C. R. Bard, Inc. & Subsidiaries$719
  • Urovant Sciences Inc$135
  • Boston Scientific$133
  • Astellas Pharma US Inc$54
  • plus $138 from 6 others

What the payments were for

  • Travel & lodging$1,26632%
  • Food & beverage$2,74068%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.23$2,034
Sumitomo Pharma America, Inc.109$794
C. R. Bard, Inc. & Subsidiaries25$719
Urovant Sciences Inc21$135
Boston Scientific3$133
Astellas Pharma US Inc3$54
AbbVie(2 entities)2$32
Profound Medical Corp.1$30
180 Medical, Inc.1$28
ABC Home Medical Supply, Inc.1$19
Rochester Medical Corporation1$14
Medtronic1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,006 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$75,001
Medicare patients
368
Services billed
2,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron592$328,186
MyrbetriqMirabegron393$233,349
Estradiol481$33,252
Methenamine Hippurate451$27,610
PremarinEstrogens, Conjugated38$17,135
Trospium Chloride ErTrospium Chloride80$13,538
Solifenacin Succinate204$12,411
ElmironPentosan Polysulfate Sodium12$12,408
Trospium Chloride73$3,867
IntrarosaPrasterone (Dhea)13$3,416
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst199$2,690
Tolterodine Tartrate ErTolterodine Tartrate23$2,345
YuvafemEstradiol21$2,191
Oxybutynin Chloride ErOxybutynin Chloride144$2,088
Fesoterodine Fumarate ErFesoterodine Fumarate18$1,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$794$328,186592 claims
Astellas Pharma US IncMyrbetriq$54$233,349393 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →